Provided by Tiger Trade Technology Pte. Ltd.

CytomX Therapeutics

5.67
+0.43008.21%
Post-market: 6.000.3300+5.82%19:38 EST
Volume:3.60M
Turnover:20.23M
Market Cap:960.70M
PE:14.08
High:5.78
Open:5.30
Low:5.30
Close:5.24
52wk High:6.35
52wk Low:0.4000
Shares:169.44M
Float Shares:113.00M
Volume Ratio:1.09
T/O Rate:3.18%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.4026
EPS(LYR):0.3774
ROE:66.76%
ROA:9.78%
PB:8.95
PE(LYR):15.02

Loading ...

CytomX Therapeutics Is Maintained at Overweight by Barclays

Dow Jones
·
Feb 04

CytomX Therapeutics nimmt an der Guggenheim Emerging Outlook: Biotech Summit und der World ADC London teil

Reuters
·
Feb 04

CytomX Therapeutics to Present at Upcoming February Conferences

GlobeNewswire
·
Feb 04

U.S. RESEARCH ROUNDUP- Ametek, Coca-Cola, Pepsico

Reuters
·
Feb 04

Cardiff Oncology Announces Executive Leadership Changes as It Transitions to Late-Stage Clinical Development

THOMSON REUTERS
·
Jan 27

Cardiff Oncology Inc - Mani Mohindru Appointed Interim CEO of Cardiff Oncology

THOMSON REUTERS
·
Jan 27

Analysts’ Top Healthcare Picks: CytomX Therapeutics (CTMX), Enhabit, Inc (EHAB)

TIPRANKS
·
Jan 22

Nasdaq Net Change Percentage Gainers & Losers

Dow Jones
·
Jan 21

CytomX Therapeutics Initiated at Buy by Guggenheim

Dow Jones
·
Jan 20

CytomX Therapeutics Is Maintained at Overweight by Piper Sandler

Dow Jones
·
Jan 20

CytomX Therapeutics initiated with a Buy at Guggenheim

TIPRANKS
·
Jan 20

CytomX Therapeutics price target raised to $10 from $6.50 at Piper Sandler

TIPRANKS
·
Jan 20

Barclays Sticks to Its Buy Rating for CytomX Therapeutics (CTMX)

TIPRANKS
·
Jan 20

U.S. RESEARCH ROUNDUP-Alphabet, Micron Technology, Microsoft

Reuters
·
Jan 20

CytomX Therapeutics Inc : Piper Sandler Raises Target Price to $10 From $6.5

THOMSON REUTERS
·
Jan 20

CytomX Therapeutics unveils advances in masked oncology therapeutics and pipeline progress

Reuters
·
Jan 15

CytomX Therapeutics: Asymmetric Upside Ahead of Pivotal CX-2051 Colorectal Cancer Data Supports Reiterated Buy and $10 Target

TIPRANKS
·
Jan 09

CytomX Therapeutics announces business update, 2026 milestones

TIPRANKS
·
Jan 08

CytomX Therapeutics to Launch Phase 1 Varseta-M Combination Study in Colorectal Cancer

Reuters
·
Jan 08

CytomX Therapeutics Inc - Cx-2051 Phase 1 Data on Track for Q1 2026

THOMSON REUTERS
·
Jan 08